Rhythm Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Rhythm Pharmaceuticals is David Meeker, benoemd in Jul2020, heeft een ambtstermijn van 4.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.23M, bestaande uit 9.7% salaris en 90.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde $ 9.25M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 5.4 jaar.
Belangrijke informatie
David Meeker
Algemeen directeur
US$7.2m
Totale compensatie
Percentage CEO-salaris | 9.7% |
Dienstverband CEO | 4.3yrs |
Eigendom CEO | 0.3% |
Management gemiddelde ambtstermijn | 4yrs |
Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$261m |
Mar 31 2024 | n/a | n/a | -US$274m |
Dec 31 2023 | US$7m | US$705k | -US$185m |
Sep 30 2023 | n/a | n/a | -US$186m |
Jun 30 2023 | n/a | n/a | -US$182m |
Mar 31 2023 | n/a | n/a | -US$181m |
Dec 31 2022 | US$3m | US$652k | -US$181m |
Sep 30 2022 | n/a | n/a | -US$181m |
Jun 30 2022 | n/a | n/a | -US$176m |
Mar 31 2022 | n/a | n/a | -US$166m |
Dec 31 2021 | US$6m | US$630k | -US$70m |
Sep 30 2021 | n/a | n/a | -US$62m |
Jun 30 2021 | n/a | n/a | -US$60m |
Mar 31 2021 | n/a | n/a | -US$56m |
Dec 31 2020 | US$15m | US$262k | -US$134m |
Sep 30 2020 | n/a | n/a | -US$132m |
Jun 30 2020 | n/a | n/a | -US$134m |
Mar 31 2020 | n/a | n/a | -US$146m |
Dec 31 2019 | US$287k | n/a | -US$141m |
Sep 30 2019 | n/a | n/a | -US$133m |
Jun 30 2019 | n/a | n/a | -US$115m |
Mar 31 2019 | n/a | n/a | -US$87m |
Dec 31 2018 | US$282k | n/a | -US$74m |
Sep 30 2018 | n/a | n/a | -US$59m |
Jun 30 2018 | n/a | n/a | -US$53m |
Mar 31 2018 | n/a | n/a | -US$47m |
Dec 31 2017 | US$268k | n/a | -US$38m |
Compensatie versus markt: De totale vergoeding ($USD 7.23M ) David } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.66M ).
Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.
CEO
David Meeker (70 yo)
4.3yrs
Tenure
US$7,230,457
Compensatie
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chairman | 4.3yrs | US$7.23m | 0.29% $ 9.3m | |
CFO & Treasurer | 7.3yrs | US$2.31m | 0.16% $ 5.2m | |
Chief Technical Officer | 4.3yrs | US$1.74m | 0.000050% $ 1.6k | |
Executive VP & Head of International | 4.1yrs | US$1.74m | 0.057% $ 1.8m | |
Executive VP & Head of North America | 4yrs | US$2.11m | 0.011% $ 363.1k | |
Corporate Controller | 1.7yrs | geen gegevens | 0.0013% $ 42.1k | |
Chief Scientific Officer | less than a year | geen gegevens | geen gegevens | |
Head of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
Senior VP & General Counsel | 4yrs | geen gegevens | geen gegevens | |
Vice President of Sales & Marketing | no data | geen gegevens | geen gegevens | |
Chief Human Resources Officer | 3.3yrs | geen gegevens | 0.022% $ 715.3k | |
Senior VP & Head of Strategy | 2.8yrs | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RYTM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chairman | 9yrs | US$7.23m | 0.29% $ 9.3m | |
Corporate Controller | 1.7yrs | geen gegevens | 0.0013% $ 42.1k | |
Independent Director | 5.4yrs | US$283.77k | 0.0049% $ 159.1k | |
Independent Director | 9yrs | US$308.77k | 0.0049% $ 159.1k | |
Lead Independent Director | 11.7yrs | US$328.77k | 0.014% $ 464.9k | |
Independent Director | 3.9yrs | US$298.77k | 0.0049% $ 159.1k | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Chairman of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Director | 5.3yrs | US$301.27k | 0.0049% $ 159.1k |
5.4yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RYTM wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).